Today: 7 February 2026
Subscribe
Browse Category

NYSE:MRK News 23 January 2026 - 6 February 2026

Merck stock rises 2% in New York as MRK traders size up outlook and a fresh RSV approval

Merck stock rises 2% in New York as MRK traders size up outlook and a fresh RSV approval

Merck shares rose about 2% to $120.72 Thursday after forecasting 2026 sales and profits below Wall Street estimates, citing patent expiries on older drugs. The company reported Q4 global sales of $16.4 billion and non-GAAP EPS of $2.04, and expects 2026 sales of $65.5–$67.0 billion. Health Canada approved ENFLONSIA for RSV prevention in infants. FDA review of WINREVAIR is set for September 21, 2026.
5 February 2026
··
Merck stock rises after-hours as cautious 2026 forecast meets new cholesterol pill headlines

Merck stock rises after-hours as cautious 2026 forecast meets new cholesterol pill headlines

Merck shares rose 2.2% to $118.33 in after-hours trading Wednesday after new data showed its experimental cholesterol drug enlicitide cut LDL by up to 60% in a major trial. The company’s 2026 revenue forecast of $65.5–$67.0 billion missed Wall Street estimates, citing pressure from off-patent drugs and U.S. pricing. Keytruda sales reached $8.37 billion last quarter, while Gardasil revenue fell 34%.
5 February 2026
···
Merck stock price rises today as MRK rallies on Keytruda strength despite soft 2026 outlook

Merck stock price rises today as MRK rallies on Keytruda strength despite soft 2026 outlook

Merck shares rose 2.8% to $119.11 by midday Wednesday after the company beat Q4 expectations, but projected 2026 revenue of $65.5–$67.0 billion, below analyst forecasts. Keytruda sales climbed 7% while Gardasil dropped 34% on weak China demand. The company cited a $2.5 billion hit from generic drugs and U.S. pricing pressure. Investors remain focused on Merck’s ability to offset declines in older products.
4 February 2026
··
Merck stock price rises after hours after choppy day — MRK traders focus on 2026 outlook and FDA dates

Merck stock price rises after hours after choppy day — MRK traders focus on 2026 outlook and FDA dates

Merck shares rose 2.2% in after-hours trading Tuesday, closing at $115.84 after the company’s 2026 revenue forecast missed Wall Street estimates. The drugmaker cited a $2.5 billion hit from patent expirations, Medicare price talks, and weaker COVID-19 pill sales. Investors are watching Keytruda demand, Gardasil’s China performance, and FDA decisions expected later in 2026.
4 February 2026
··
Dow Jones slips 167 points on AI disruption fears; Alphabet, Amazon earnings next

Dow Jones slips 167 points on AI disruption fears; Alphabet, Amazon earnings next

The Dow Jones Industrial Average fell 166.67 points, or 0.34%, to 49,240.99 Tuesday as tech and software stocks dropped on AI disruption fears. IBM and Salesforce weighed heavily, while Walmart rose 3% to surpass a $1 trillion market cap. The S&P 500 lost 0.84% and the Nasdaq slid 1.43%. Earnings from Alphabet and Amazon are due next.
3 February 2026
···········
Merck stock rises despite cautious 2026 outlook as patent losses loom

Merck stock rises despite cautious 2026 outlook as patent losses loom

Merck shares rose 3.1% to $116.86 after fourth-quarter earnings beat estimates, with Keytruda sales up 7% to $8.37 billion. The company forecast 2026 sales of $65.5–$67.0 billion, below Wall Street expectations, citing patent expirations and pricing pressure. Gardasil sales fell 34% to $1.03 billion. The FDA accepted Merck’s application for Winrevair, with a decision expected by September 2026.
3 February 2026
··
Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

The Health Care Select Sector SPDR Fund (XLV) rose 0.6% to $154.74 Friday, while the S&P 500 fell 0.43%. Healthcare and consumer staples were the only S&P sectors in positive territory as investors shifted to defensive stocks. Major managed-care shares lagged after a minimal proposed Medicare Advantage rate hike. Pfizer, Merck, and Eli Lilly report earnings next week.
1 February 2026
·····
Merck stock jumps to $110 as MRK heads into a big earnings week

Merck stock jumps to $110 as MRK heads into a big earnings week

Merck shares rose 1.8% to $110.27 Friday, outperforming a falling S&P 500 and closing about 2% below their 52-week high. Trading volume topped 19 million shares, well above rivals. Investors await Merck’s Feb. 3 earnings call and new inflation data that could affect rate expectations. Markets reacted to President Trump’s Fed pick and mixed inflation signals.
31 January 2026
···
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
······
Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call

Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call

Merck shares rose 1.2% to $109.64 Friday afternoon, outperforming a falling S&P 500. Health care stocks attracted buyers as inflation data came in hotter than expected and Donald Trump named Kevin Warsh as Federal Reserve chair. Investors are watching for Merck’s Feb. 3 earnings call, with focus on 2026 guidance and Keytruda sales trends.
30 January 2026
···
Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna shares fell 6.09% to $48.71 Friday after CEO Stéphane Bancel said the company will scale back new late-stage vaccine trials, citing U.S. resistance and policy delays. The drop followed a midweek rally on positive cancer vaccine data with Merck. Investors await Moderna’s Feb. 13 results for further updates. U.S. markets are closed until Monday.
24 January 2026
···
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.
23 January 2026
·····
Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer shares fell 1.9% to $25.62 Friday as the stock went ex-dividend, nearly matching the $0.43 payout. The drop outpaced the health-care sector, with Moderna tumbling over 7% and Merck down 1%. Policy changes under Health Secretary Robert F. Kennedy Jr. have unsettled vaccine makers. Pfizer reports quarterly results and hosts a webcast on Feb. 3.
23 January 2026
·····
1 2 3 … 5

Stock Market Today

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

7 February 2026
Bank of America shares rose 2.89% Friday to $56.53, tracking a rally in U.S. financial stocks as the Dow closed above 50,000. The bank will redeem its Series DD preferred stock and related depositary shares on March 10 at $1,000 per share. CEO Brian Moynihan donated 100,000 shares on Feb. 4, a regulatory filing showed. Key U.S. jobs and inflation data are due next week after delays.
Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

7 February 2026
Oracle shares jumped 4.65% to $142.82 Friday, ending an eight-day slide but remaining down 22% since Jan. 27. The company has set up a $20 billion at-the-market stock program and completed a $25 billion senior notes sale to fund cloud expansion. Oracle’s liabilities stood at $174.5 billion as of Nov. 30, 2025, before the new financing. Investors remain focused on dilution risks and the pace of capacity growth.
Go toTop